Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Share-based Compensation (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Share-based Compensation for 16 consecutive years, with $43321.0 as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 71.06% to $43321.0 in Q4 2025 year-over-year; TTM through Nov 2025 was $417101.0, a 46.6% decrease, with the full-year FY2025 number at $417101.0, down 46.6% from a year prior.
  • Share-based Compensation was $43321.0 for Q4 2025 at Cryo Cell International, up from $36780.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $313000.0 in Q1 2023 to a low of $31896.0 in Q1 2022.
  • A 5-year average of $138904.6 and a median of $148064.0 in 2024 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 881.31% in 2023, then crashed 77.53% in 2025.
  • Cryo Cell International's Share-based Compensation stood at $68131.0 in 2021, then skyrocketed by 120.98% to $150559.0 in 2022, then rose by 16.44% to $175310.0 in 2023, then decreased by 14.61% to $149693.0 in 2024, then plummeted by 71.06% to $43321.0 in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Share-based Compensation are $43321.0 (Q4 2025), $36780.0 (Q3 2025), and $40000.0 (Q2 2025).